MEDIFUSION

Details for Australian Trade Mark No. 1369043 (hide)

Owner Alkermes, Inc.

Convention US 7 January 2010 77/906,660

Service Davies Collison Cave

Various Convention priority claimed: 7 January 2010, United States of America, No. 77/906,660 in respect of "PHARMACEUTICAL COMPOUNDS; PROTEIN FUSION COMPOUNDS; FUSION COMPOUNDS FOR THE DELIVERY OF PHARMACEUTICALS; PRODRUGS; DERIVATIVES OF THE ACTIVE INGREDIENTS

Filing Date 28 June 2010

Classes

Class 5 Pharmaceuticals, namely pro-drugs, protein fusion compounds, and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases, cancer, inflammatory diseases, respiratory and infectious diseases, metabolic diseases, blood disorders and autoimmune diseases; pharmaceutical compounds, namely, prodrugs, protein fusions compunds and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous systems diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases, cancer, inflammatory diseases, respiratory and infectious diseases, metabolic diseases, blood disorders and autoimmune diseases

Event Publications

15 July 2010 Application filed

12 May 2011 Application Accepted

25 August 2011 Trade Mark Registered/Protected

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the ATMOSS Australian Trade Mark On-line Search System.

Next and Previous Trademarks/Applications

1369044-EduRoo

1369042-LinksLiving